The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/8/2150 |
| _version_ | 1797560419828629504 |
|---|---|
| author | Nicole E. James Morgan Woodman Paul A. DiSilvestro Jennifer R. Ribeiro |
| author_facet | Nicole E. James Morgan Woodman Paul A. DiSilvestro Jennifer R. Ribeiro |
| author_sort | Nicole E. James |
| collection | DOAJ |
| description | Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic approaches, centered upon programmed cell death 1 (PD-1) inhibitors. While PD-1 monotherapies have only exhibited modest responses for patients, it has been theorized that in order to enhance EOC patient response to immunotherapy, combinatorial regimens must be investigated. In this review, unique challenges to EOC PD-1 response will be discussed, along with a comprehensive description of both preclinical and clinical studies evaluating PD-1-based combinatorial therapies. Promising aspects of PD-1-based combinatorial approaches are highlighted, while also discussing specific preclinical and clinical areas of research that need to be addressed, in order to optimize EOC patient immunotherapy response. |
| first_indexed | 2024-03-10T18:00:16Z |
| format | Article |
| id | doaj.art-af799cc0357e4971a6207e18eab40c65 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T18:00:16Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-af799cc0357e4971a6207e18eab40c652023-11-20T08:56:54ZengMDPI AGCancers2072-66942020-08-01128215010.3390/cancers12082150The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian CancerNicole E. James0Morgan Woodman1Paul A. DiSilvestro2Jennifer R. Ribeiro3Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI 02905, USAProgram in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI 02905, USAProgram in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI 02905, USAProgram in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI 02905, USAEpithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic approaches, centered upon programmed cell death 1 (PD-1) inhibitors. While PD-1 monotherapies have only exhibited modest responses for patients, it has been theorized that in order to enhance EOC patient response to immunotherapy, combinatorial regimens must be investigated. In this review, unique challenges to EOC PD-1 response will be discussed, along with a comprehensive description of both preclinical and clinical studies evaluating PD-1-based combinatorial therapies. Promising aspects of PD-1-based combinatorial approaches are highlighted, while also discussing specific preclinical and clinical areas of research that need to be addressed, in order to optimize EOC patient immunotherapy response.https://www.mdpi.com/2072-6694/12/8/2150PD-1ovarian cancerimmunotherapy |
| spellingShingle | Nicole E. James Morgan Woodman Paul A. DiSilvestro Jennifer R. Ribeiro The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer Cancers PD-1 ovarian cancer immunotherapy |
| title | The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer |
| title_full | The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer |
| title_fullStr | The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer |
| title_full_unstemmed | The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer |
| title_short | The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer |
| title_sort | perfect combination enhancing patient response to pd 1 based therapies in epithelial ovarian cancer |
| topic | PD-1 ovarian cancer immunotherapy |
| url | https://www.mdpi.com/2072-6694/12/8/2150 |
| work_keys_str_mv | AT nicoleejames theperfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT morganwoodman theperfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT pauladisilvestro theperfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT jenniferrribeiro theperfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT nicoleejames perfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT morganwoodman perfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT pauladisilvestro perfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer AT jenniferrribeiro perfectcombinationenhancingpatientresponsetopd1basedtherapiesinepithelialovariancancer |